Chronic lower extremity arterial occlusive diseases

DOI: https://doi.org/10.29296/25877305-2021-10-05
Download full text PDF
Issue: 
10
Year: 
2021

K. Smirnov; S. Makarov, MD Research Institute for Complex Problems of Cardiovascular Diseases,
Kemerovo

According to the WHO, cardiovascular diseases are the main global cause of death (16% of the total deaths). Among them, chronic lower extremity arterial occlusive diseases (CLEAODs) occupy a special place, the prevalence of which reaches 10-15% of the entire world’s population. CLEAODs are blood vessel diseases, in which arterial blood flow to the affected limb is disrupted due to stenosis or complete occlusion of the arteries with the development of chronic ischemia. The paper considers the main clinical-and-anamnestic and psychosocial characteristics of patients with CLEAODs, as well as risk factors and innovative treatment and rehabilitation methods. The presented results of an analysis of current randomized clinical trials, the recommendations of the European Society of Cardiology on the diagnosis and treatment of peripheral artery diseases can be used as an addition in clinical practice.

Keywords: 
cardiology
chronic lower extremity arterial occlusive diseases
peripheral atherosclerosis
literature review



It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. 1. Sergienko S.V., Ansheles A.A. Kuharchuk V.V. Ateroskleroz i dislipidemii: sovremennye aspekty patogeneza, diagnostiki i lechenija. M.: PatiSS, 2017 [Sergienko S.V., Ansheles A.A., Kukharchuk V.V. Atherosclerosis and dyslipidemia: modern aspects of pathogenesis, diagnosis and treatment. M.: Patiss, 2017 (in Russ.)].
  2. 2. Gavrilenko A.V., Omarzhanov O.A., Abramjan A.V. Mikrotsirkuljatsija u bol'nyh hronicheskoj ishemiej nizhnih konechnostej. Angiologija i sosudistaja hirurgija. 2003; 9 (2): 130–5 [Gavrilenko A.V., Omarzhanov O.A., Abramyan A.V. Mikrotsirkulyatsiya u bol’nykh khronicheskoi ishemiei nizhnikh konechnostei. Angiologists and Vascular Surgeons. 2003; 9 (2): 130–5 (in Russ.)].
  3. 3. Koshkin V.M., Sergeeva N.A., Kuznetsov M.R. i dr. Konservativnaja terapija bol'nyh hronicheskimi obliterirujuschimi zabolevanijami arterij nizhnih konechnostej. Meditsinskij sovet. 2015; 8: 6–9 [Koshkin V.M., Sergeeva N.A., Kuznetsov M.R. et al. Conservative therapy in patients with chronic obliterating diseases of lower limb arteries. Current views. Meditsinskiy sovet = Medical Council. 2015; 8: 6–9 (in Russ.)]. DOI: 10.21518/2079-701X-2015-8-6-9
  4. 4. Obolenskij V.N., Janshin D.V., Isaev G.A. i dr. Hronicheskie obliterirujuschie zabolevanija arterij nizhnih konechnostej – diagnostika i taktika lechenija. RMZh. 2010; 18 (17): 1049–54 [Obolenskii V.N., Yanshin D.V., Isaev G.A. et al. Khronicheskie obliteriruyushchie zabolevaniya arterii nizhnikh konechnostei – diagnostika i taktika lecheniya. RMJ. 2010; 18 (17): 1049–54 (in Russ.)].
  5. 5. Selvin E., Erlinger T.P. Prevalence and risk factors for peripheral arterial disease in the Unated States: results from the National Health and Nutrition Examination Survey, 1999–2000. Circulation. 2004; 11 (6): 738–43. DOI: 10.1161/01.CIR.0000137913.26087.F0
  6. 6. Gavrilenko A.V., Skrylev S.I., Kuzubova E.A. Sovremennye vozmozhnosti i perspektivy hirurgicheskogo lechenija bol'nyh s kriticheskoj ishemiej nizhnih konechnostej. Angiologija i sosudistaja hirurgija. 2002; 8 (4): 80–6 [Gavrilenko A.V., Skrylev S.I., Kuzubova E.A. Sovremennye vozmozhnosti i perspektivy khirurgicheskogo lecheniya bol’nykh s kriticheskoi ishemiei nizhnikh konechnostei. Angiologists and Vascular Surgeons. 2002; 8 (4): 80–6 (in Russ.)].
  7. 7. Drozdov S.A. Klinika, diagnostika i metody lechenija perifericheskogo ateroskleroza. Trudnyj patsient. 2005; 10: 54–8 [Drozdov S.A. Klinika, diagnostika i metody lecheniya perifericheskogo ateroskleroza. Trudnyi patsient. 2005; 10: 54–8 (in Russ.)].
  8. 8. Zudin A.M., Zasorina M.A., Orlova M.A. Epidemiologicheskie aspekty hronicheskoj kriticheskoj ishemii nizhnih konechnostej. Hirurgija. 2014; 10: 78–82 [Zudin A.M., Zasorina M.A., Orlova M.A. Epidemiology of chronic critical limb ischemia. Khirurgiya. 2014; 10: 78–82 (in Russ.)].
  9. 9. Pokrovskij A., Dan V., Zotikov A. i dr. Kompleksnoe lechenie bol'nyh obliterirujuschimi zabolevanijami arterij nizhnih konechnostej bez kriticheskoj ishemii. Vrach. 2011; 14: 57–60 [Pokrovsky A., Dan V., Zotikov A. et al. Combination treatment in patients with obliterating diseases of lower extremity arteries without critical ischemia. Vrach. 2011; 14: 57–60 (in Russ.)].
  10. 10. Norgren L., Hiatt W. G., Dormandi J. A. et al. Inter-society consensus for the management of peripheral arterial disease. Eur J Vasc Endovasc Surg. 2007; 33: 1–70. DOI: 10.1016/j.jvs.2006.12.037
  11. 11. Reinecke H., Unrath M., Freisinger E. et al. Peripheral arterial disease and critical limb ischaemia: still poor outcomes and lack of guideline adherence. Eur Heart J. 2015; 36 (15): 932–8. DOI: 10.1093/eurheartj/ehv006
  12. 12. Serdechno-sosudistye zabolevanija [Elektronnyj resurs] Informatsionnyj bjulleten'. VOZ. 2015; №317 [Serdechno-sosudistye zabolevaniya [Elektronnyi resurs] Informatsionnyi byulleten’. VOZ. 2015; №317 (in Russ.)]. URL: http://www.who.int/mediacentr/factsheets/fs317/ru
  13. 13. Natsional'nye rekomendatsii po vedeniju patsientov s sosudistoj arterial'noj patologiej. Chast' 1. Perifericheskie arterii. M., 2010; 78 s. [Natsional’nye rekomendatsii po vedeniyu patsientov s sosudistoi arterial’noi patologiei. Chast’ 1. Perifericheskie arterii. M., 2010; 78 s. (in Russ.)].
  14. 14. Natsional'nye rekomendatsii po vedeniju po vedeniju patsientov s zabolevanijami arterij nizhnih konechnostej. Angiologija i sosudistaja hirurgija. 2013; 19 (2, Pril.): 68 [Natsional’nye rekomendatsii po vedeniyu po vedeniyu patsientov s zabolevaniyami arterii nizhnikh konechnostei. Angiologists and Vascular Surgeons. 2013; 19 (2, Pril.): 68 (in Russ.)].
  15. 15. Shval'b P.G., Kalinin R.E., Kachinskij A.E. Konservativnoe lechenie zabolevanija perifericheskih sosudov. Pod red. P.G. Shval'ba, D.R. Rakity. Rjazan': Poligraf. kombinat «Tigel'», 2008; 91 s. [Shval’b P.G., Kalinin R.E., Kachinskii A.E. Konservativnoe lechenie zabolevaniya perifericheskikh sosudov. Pod red. P.G. Shval’ba, D.R. Rakity. Ryazan’: Poligraf. kombinat «Tigel’», 2008; 91 s. (in Russ.)].
  16. 16. TASC Working Group: Management of peripheral arterial disease. J Vasc Surg. 2000; 31 (1): 1–296.
  17. 17. Nehler M.R., Duval S., Diao L. et al. Epidemiology of peripheral arterial disease and critical limb ischemia in an insured national population. J Vasc Surg. 2014; 60 (3): 686–95.e2. DOI: 10.1016/j.jvs.2014.03.290
  18. 18. Kalinin R.E., Mzhavanadze N.D., Deev R.V. Peremezhajuschajasja hromota: lechebnaja taktika praktikujuschego vracha. Lechaschij vrach. 2013; 7: 65 [Kalinin R.E., Mzhavanadze N.D., Deev R.V. Peremezhayushchayasya khromota: lechebnaya taktika praktikuyushchego vracha. Lechashchii vrach. 2013; 7: 65 (in Russ.)].
  19. 19. Pogosova G.V. Priznanie znachimosti psihoemotsional'nogo stressa v kachestve serdechno-sosudistogo faktora riska pervogo porjadka. Kardiologija. 2007; 2: 65–72 [Pogosova G.V. Acknowledgement of its value as a first order cardiovascular risk factor. Kardiologiya. 2007; 2: 65–72 (in Russ.)].
  20. 20. Natsional'nye rekomendatsii po diagnostike i lecheniju zabolevanij arterij nizhnih konechnostej. M., 2019 [Natsional’nye rekomendatsii po diagnostike i lecheniyu zabolevanii arterii nizhnikh konechnostei. M., 2019 (in Russ.)].
  21. 21. Ruf R.R.. Rol' vospalenija v razvitii ateroskleroza i serdechno-sosudistyh sobytij. Sibirskoe meditsinskoe obozrenie. 2015; 6: 23–7 [Artyukhov I.P., Greenstein Y.I. The role of inflammation in the development of atherosclerosis and cardiovascular events. Siberian medical review. 2015; 6: 23–7 (in Russ.)];
  22. 22. Alshaarawy O., Elbaz H.A., Andrew M.E. The association of urinary polycyclic aromatic hydrocarbon biomarkers and cardiovascular disease in the US population. Environ Int. 2016; 89–90: 174–8. DOI: 10.1016/j.envint.2016.02.006
  23. 23. Kutihin A.G., Sinitskij M.Ju., Ponasenko A.V. Rol' mutageneza v razvitii ateroskleroza. Obzory literatury. Kemerovo: FGBNU «Nauchno-issledovatel'skij institut kompleksnyh problem serdechno-sosudistyh zabolevanij», 2016 [Kutikhin A.G., Sinitskiy M.Y., Ponasenko A.V. Mutagenesis role in atherosclerosis development. Lit. rev. Kemerovo: Federal State Science Institution «Research Institute of complex problems of cardiovascular diseases», 2016 (in Russ.)].
  24. 24. Tmojan N.A., Ezhov M.V., Afanas'eva O.I. i dr. Lipoproteid(a) kak nezavisimyj prediktor stenozirujuschego ateroskleroza perifericheskih arterij. Kompleksnye problemy serdechno-sosudistyh zabolevanij. 2017; 6 (S4): 39–40 [Tmoyan N.A., Ezhov M.V., Afanas’eva O.I. et al. Lipoproteid(a) kak nezavisimyi prediktor stenoziruyushchego ateroskleroza perifericheskikh arterii. Kompleksnye problemy serdechno-sosudistykh zabolevanii. 2017; 6 (S4): 39–40 (in Russ.)].
  25. 25. Fatemi S., Gottsäter A., Zarrouk M. et al. Lp-PLA2 activity and mass and CRP are associated with incident symptomatic peripheral arterial disease. Sci Rep. 2019; 9 (1): 5609. DOI: 10.1038/s41598-019-42154-5
  26. 26. Chur N.N., Kondratenko G.G., Kazuschik V.L. Ateroskleroz nizhnih konechnostej. Hronicheskaja arterial'naja nedostatochnost': uchebno-metodicheskoe posobie. Minsk: BGMU, 2017; 31 s. [Chur N.N., Kondratenko G.G., Kazushchik V.L. Ateroskleroz nizhnikh konechnostei. Khronicheskaya arterial’naya nedostatochnost’: uchebno-metodicheskoe posobie. Minsk: BGMU, 2017; 31 s. (in Russ.)].
  27. 27. Schaper N.C., Andros G., Apelqvist J. et al. Specific guidelines for the diagnosis and treatment of peripheral arterial disease in a patient with diabetes and ulceration of the foot 2011. Diabetes Metab Res Rev. 2012; 28 (Suppl 1): 236–7. DOI: 10.1002/dmrr.2252
  28. 28. Hvostovoj V.V., Bakulin I.V. K probleme rannih posleoperatsionnyh trombozov v rekonstruktivnoj sosudistoj hirurgii. Mat-ly konf. molodyh uchenyh: «Rekonstruktsija – osnova sovremennoj hirurgii». M.: Air-Art, 1999; s. 61–2 [Khvostovoi V.V., Bakulin I.V. K probleme rannikh posleoperatsionnykh trombozov v rekonstruktivnoi sosudistoi khirurgii. Mat-ly konf. molodykh uchenykh: «Rekonstruktsiya – osnova sovremennoi khirurgii». M.: Air-Art, 1999; s. 61–2 (in Russ.)].
  29. 29. Slim H., Tiwari A., Ahmed A., Distal versus ultradistal bypass grafts: am-putation-free survival and patency rates in patients with critical leg ischaemia. Eur J Vasc Endovasc Surg. 2011; 42 (1): 83–8. DOI: 10.1016/j.ejvs.2011.03.016
  30. 30. Kechagias A., Ylönen K., Kechagias G. et.al. Limits of infrainguinal by-pass surgery for critical leg ischemia in high-risk patients (Finnvasc score 3-4). Ann Vasc Surg. 2012; 26 (2): 213–8.
  31. 31. Denollet J., Sys S.U., Brutsaert D.L. Personality and mortality after myocardial infarction. Psychosom Med. 1995; 57: 582–91. DOI: 10.1097/00006842-199511000-00011
  32. 32. Kuznetsov M.R., Magnitskij L.A. Vozmozhnosti ambulatornogo lechenija hronicheskoj ishemii nizhnih konechnostej. Ambulatornaja hirurgija. 2017; 3–4: 30–5 [Kuznetsov M.R., Magnitsky L.A. Opportunities for outpatient treatment of chronic lower limb ischemia. Outpatient surgery. 2017; 3–4: 30–35 (in Russ.)];
  33. 33. Rekomendatsii Evropejskogo obschestva kardiologov po diagnostike i lecheniju zabolevanij perifericheskih arterij. M., 2012 [Rekomendatsii Evropeiskogo obshchestva kardiologov po diagnostike i lecheniyu zabolevanii perifericheskikh arterii. M., 2012 (in Russ.)].
  34. 34. Sapelkin S.V., Kuznetsov M.R. Konservativnoe lechenie bol'nyh s zabolevanijami perifericheskih arterij: vozmozhnosti i suschestvujuschie problemy. Meditsina (Almaty). 2018; 8: 8–13 [Sapelkin S.V., Kuznetsov M.R. Conservative treatment of patients with peripheral arterial disease: possibilities and existing problems. Medicine (Almaty). 2018; 8: 8–13 (in Russ.)]. DOI: 10:31082/1728-452X-2018-194-8-8-13
  35. 35. Graham I., Atar D., Borch-Johnsen K. et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur J Cardiovasc Prev Rehabil. 2007; 14 (Suppl 2): E1–40. DOI: 10.1097/01.hjr.0000277984.31558.c4
  36. 36. Sidney C.S., Jerilyn A., Steven N.B. et al. AHA/ACC Guidelines for Secondary Prevention for Patients with Coronary and Other Atherosclerotic Vascular Disease: 2006 Update: Endorsed by the National Heart, Lung, and Blood Institute. Circulation. 2006; 113: 2363–72. DOI: 10.1161/CIRCULATIONAHA.106.174516
  37. 37. Patrono C., Andreotti F., Arnesen H. et al Antiplatelet Agents for the Treatment and Prevention of Atherothrombosis. Eur Heart J. 2011; 32 (23): 2922–32. DOI: 10.1093/eurheartj/ehr373
  38. 38. Eikelboom J.W., Hirsh J., Spencer F.A. et al. Antiplatelet Drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed:American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141 (2 Suppl): e89S–e119S. DOI: 10.1378/chest.11-2293
  39. 39. De Luca L., Leonardi S., Smecca I. M. et al. On behalf of the EYESHOT Investigators. Contemporary antithrombotic strategies in patients with acute coronary syndromes managed without revascularization: insights from the EYESHOT study. Eur Heart J Cardiovasc Pharmacother. 2015; 1: 168–78. DOI: 10.1093/ehjcvp/pvv006
  40. 40. Eikelboom J.W., Connolly S.J., Bosch J. et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med. 2017; 377: 1319–30. DOI: 10.1056/NEJMoa1709118
  41. 41. Kozlov D.V., Vinokurov I.A. Perspektivy ispol'zovanija novogo antiagregantnogo preparata Pletaks® (tsilostazol) v lechenii zabolevanij perifericheskih arterij. Lechenie i profilaktika. 2019; 9 (1): 76–80 [Kozlov D.V., Vinokurov I.A. Application prospects for the new antiplatelet medication «Pletax®» (cilostazol) in the treatment of peripheral artery disease. Treatment and prevention. 2019; 9 (1): 76–80 (in Russ.)].
  42. 42. Hirschhorn J.N., Daly M.J. Genome-wide association studies for common diseases and complex traits. Nat Rev Genet. 2005; 6: 95–108. DOI: 10.1038/nrg1521
  43. 43. Conte M.S. et al. Society for Vascular Surgery Practice Guidelines for Atherosclerotic Occlusive Disease of the Lower Extremities: Management of Asymptomatic Disease and Claudication. J Vasc Surg. 2016; 61 (Suppl 3): 1S–74S. DOI: 10.1016/j.jvs.2014.12.009
  44. 44. Natsional'nye rekomendatsii po vedeniju patsientov s zabolevanijami arterij nizhnih konechnostej. Pod red. A.V. Pokrovskogo. M., 2013; 74 s. [Natsional’nye rekomendatsii po vedeniyu patsientov s zabolevaniyami arterii nizhnikh konechnostei. Pod red. A.V. Pokrovskogo. M., 2013; 74 s. (in Russ.)].
  45. 45. Stevens J.W., Simpson E., Harnan S. et al. Systematic review of the efcacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication. Br J Surg. 2012; 99: 1630–8. DOI: 10.1002/bjs.8895
  46. 46. Pokrovskij A.V., Chupin A.V., Parshin P.Ju. i dr. Primenenie genericheskogo prostaglandina E1 VAP 20® u bol'nyh s kriticheskoj ishemiej nizhnih konechnostej: Prospektivnoe issledovanie. Angiologija i sosudistaja hirurgija. 2013; 19 (2): 17–24 [Pokrovsky A.V., Chupin A.V., Parshin P.Yu. et al. Administration of the generic prostaglandin E1 VAP 20® in patients with lower limb critical ischaemia: a prospective study. Angiology and vascular surgery. 2013; 19 (2): 17–24 (in Russ.)].
  47. 47. Chervjakov Ju.V., Ha H.N., Klimov A.E. i dr. Blizhajshie rezul'taty konservativnogo lechenija «nerekonstruktabel'nyh» bol'nyh s kriticheskoj ishemiej nizhnih konechnostej s troficheskimi izmenenijami. Angiologija i sosudistaja hirurgija. 2019; 25 (2): 11–5 [Chervyakov Yu.V., Kha Kh.N., Klimov A.E. et al. Immediate results of conservative treatment of patients with unreconstructable critical limb ischaemia and trophic changes. Angiology and vascular surgery. 2019; 25 (2): 11–5 (in Russ.)]. DOI: 10.33529/ANGIO2019201
  48. 48. Walter D.H., Krankenberg H., Balzer J.O. et al. PROVASA Investigators. Intraarterial administration of bone marrow mononuclear cells in patients with critical limb ischemia: a randomized-start, placebocontrolled pilot trial (PROVASA). Circ Cardiovasc Interv. 2011; 4 (1): 26–37. DOI: 10.1161/CIRCINTERVENTIONS.110.958348
  49. 49. Bisdas T., Borowski M., Stavroulakis K., et al. CRITISCH Collaborators. Endovascular therapy versus bypass surgery as first-line treatment strategies for critical limb ischemia: Results of the interim analysis of the CRITISCH registry. JACC Cardiovasc Interv. 2016; 9 (24): 2557–65. DOI: 10.1016/j.jcin.2016.09.039
  50. 50. Mitichkin A.E., Papojan S.A., Schegolev A.A. i dr. Sochetannye endovaskuljarnye i rekonstruktivnye operatsii pri mnogoetazhnyh porazhenijah arterij nizhnih konechnostej. Annaly hirurgii. 2016; 21 (3): 187–92 [Mitichkin A.E., Papoyan S.A., Shegolev A.A. et al. Hybrid endovascular and open reconstructive procedure in severe multilevel lower extremity arterial disease. Annaly khirurgii = Annals of Surgery, Russian journal. 2016; 21 (3): 187–92 (in Russ.)]. DOI: 10.18821/1560-9502- 2016-21-3-187-192;
  51. 51. Kazakov Ju.I., Kazakov A.Ju., Kas'janenko A.P. Pokazanija k operatsii bedrenno-podkolennogo shuntirovanija v izolirovannyj svobodnyj segment podkolennoj arterii u patsientov s kriticheskoj ishemiej nizhnih konechnostej. Bjulleten' NTsSSH im. A.N. Bakuleva RAMN. 2008; 6: 114 [Kazakov Yu.I., Kazakov A.Yu., Kas’yanenko A.P. Pokazaniya k operatsii bedrenno-podkolennogo shuntirovaniya v izolirovannyi svobodnyi segment podkolennoi arterii u patsientov s kriticheskoi ishemiei nizhnikh konechnostei. Byulleten’ NTsSSKh im. A.N. Bakuleva RAMN. 2008; 6: 114 (in Russ.)].
  52. 52. Steiner S., Schmidt A., Scheinert D. Interventional angiology: Endovascular treatment of chronic and acute limb ischemia. Internist (Berl). 2019; 60 (2): 149–60. DOI: 10.1007/s00108-018-0549-4
  53. 53. Management of Isolated Atherosclerotic Stenosis of the Common Femoral Artery: A Review of the Literature. Department of Cardiovascular Medicine, Yale New Haven Hospital, New Haven, CT, USA. Department of Surgery, Vascular Surgery, Yale New Haven Hospital, New Haven, CT, USA. 2017.
  54. 54. Bokerija L.A., Bokerija O.L., Poljakova U.A. Naruzhnaja kontrpul'satsija v lechenii bol'nyh ishemicheskoj bolen'ju serdtsa: ot mehanizmov dejstvija do klinicheskih rezul'tatov. Grudnaja i serdechno-sosudistaja hirurgija. 2012; 2: 47–51 [Bockeria L.A., Bockeria O.L., Polyakova U.A. External counterpulsation in treatment of coronary artery disease patients: from mechanisms of action to clinical outcomes. Russian Journal of Thoracic and Cardiovascular Surgery. 2012; 2: 47–51 (in Russ.)].
  55. 55. Montminy M.L., Gauvin V., Turcotte S. et al. Factors Influencing the Prescription of Cardiovascular Preventive Therapies in Patients with Peripheral Arterial Disease. PLoS One. 2016; 11 (2): e0148069. DOI: 10.1371/journal.pone.0148069
  56. 56. Gabrusenko S.A., Malahov V.V., Sergienko I.V. i dr. Pervyj opyt primenenija v Rossii lechebnogo metoda naruzhnoj kontrpul'satsii u bol'nyh ishemicheskoj bolezn'ju serdtsa. Ter arh. 2006; 9: 27–33 [Gabrusenko S.A., Malakhov V.V., Sergienko I.V. et al. Pilot experience in russia with external contrapulsation in patients with coronary heart disease. Ter arkh. 2006; 9: 27–33 (in Russ.)].
  57. 57. Sergienko I.V., Ezhov M.V., Malahov V.V. i dr. Metod naruzhnoj kontrpul'satsii v lechenii bol'nyh ishemicheskoj bolezn'ju serdtsa. Kardiologija. 2004; 11: 92–6 [Sergienko I.V., Ezhov M.V., Malakhov V.V. et al. Metod naruzhnoi kontrpul’satsii v lechenii bol’nykh ishemicheskoi bolezn’yu serdtsa. Kardiologiya. 2004; 11: 92–6 (in Russ.)].
  58. 58. Savel'ev V.S., Koshkin V.M., Karalkin A.V. Patogenez i konservativnoe lechenie tjazhelyh stadij obliterirujuschego ateroskleroza arterij nizhnih konechnostej. M.: MIA, 2010 [Savel’ev V.S., Koshkin V.M., Karalkin A.V. Patogenez i konservativnoe lechenie tyazhelykh stadii obliteriruyushchego ateroskleroza arterii nizhnikh konechnostei. M.: MIA, 2010 (in Russ.)].
  59. 59. Dzhaff M.R., Moler E.R. Zabolevanija perifericheskih arterij. M.: GEOTAR-Media, 2010 [Dzhaff M.R., Moler E.R. Zabolevaniya perifericheskikh arterii. M.: GEOTAR-Media, 2010 (in Russ.)].
  60. 60. Novik A.A., Matveev S.A., Ionova T.I. i dr. Otsenka kachestva zhizni bol'nogo v meditsine. Klinicheskaja meditsina. 2000; 2: 10–3 [Novik A.A., Matveev S.A., Ionova T.I. et al. Otsenka kachestva zhizni bol’nogo v meditsine. Klinicheskaya meditsina. 2000; 2: 10–3 (in Russ.)].
  61. 61. Vinnik Ju.S., Dunaevskaja S.S., Podrezenko E.S. Kachestvo zhizni patsientov s obliterirujuschim aterosklerozom sosudov nizhnih konechnostej po dannym oprosnika SF-36. Fundamental'nye issledovanija. 2015; 1–3: 467–9 [Vinnik Y.S., Dunaevskaya S.S., Podrezenko E.S. Quality of life of patients the obliterating atherosclerosis of vessels of the lower extremities according to SF-36 questionnaire. Fundamental research. 2015; 1–3: 467–9 (in Russ.)]. URL: http://www.fundamental-research.ru/ru/article/view?id=37039
  62. 62. Ware J.E. Measuring patients’ views: the optimum outcome measure. SF 36: a valid, reliable assessment of health from the patient’s point of view. BMJ. 1993; 306: 1429–30. DOI: 10.1136/bmj.306.6890.1429
  63. 63. Chervjakov Ju.V., Vlasenko O.N. Kachestvo zhizni u patsientov s aterosklerozom nizhnih konechnostej pri ispol'zovanii standartnogo lechenija i terapevticheskogo angiogeneza. Ter arh. 2017; 89 (9): 87–92 [Chervyakov Y.V., Vlasenko O.N. Quality of life in patients with lower extremity atherosclerosis during standard treatment and therapeutic angiogenesis. Ter arkh. 2017; 89 (9): 87–92 (in Russ.)]. DOI: 10.17116/terarkh201789987-92
  64. 64. Barbarash L.S., Artamonova G.V., Makarov S.A. Innovatsionnaja model' organizatsii spetsializirovannoj pomoschi pri boleznjah sistemy krovoobraschenija. Kemerovo: Kuzbassvuzizdat, 2008; 167 s. [Barbarash L.S., Artamonova G.V., Makarov S.A. Innovatsionnaya model’ organizatsii spetsializirovannoi pomoshchi pri boleznyakh sistemy krovoobrashcheniya. Kemerovo: Kuzbassvuzizdat, 2008; 167 s. (in Russ.)].
  65. 65. Artamonova G.V., Krjuchkov D.V., Makarov S.A. i dr. Integratsija innovatsionnyh tehnologij upravlenija kardiologicheskoj sluzhboj. Kompleksnye problemy serdechno-sosudistyh zabolevanij. 2012; 1: 35–9 [Artamonova G.V., Kruchkov D.V., Makarov S.A. et al. Integration of innovative technologies of management by cardiological service. Complex Issues of Cardiovascular Diseases. 2012; 1: 35–9 (in Russ.)]. DOI: 10.17802/2306-1278-2012-1-35-39
  66. 66. Kumbhani D.J., Steg P.G., Cannon C.P. et al. REACH Registry Investigators. Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry. Eur Heart J. 2014; 35 (41): 2864–72. DOI: 10.1093/eurheartj/ehu080